RT Journal Article
SR Electronic
T1 Investigating the sources of variable impact of pathogenic variants in monogenic metabolic conditions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.14.23295564
DO 10.1101/2023.09.14.23295564
A1 Wei, Angela
A1 Border, Richard
A1 Fu, Boyang
A1 Cullina, Sinéad
A1 Brandes, Nadav
A1 Jang, Seon-Kyeong
A1 Sankararaman, Sriram
A1 Kenny, Eimear E.
A1 Udler, Miriam S.
A1 Ntranos, Vasilis
A1 Zaitlen, Noah
A1 Arboleda, Valerie A.
YR 2024
UL http://medrxiv.org/content/early/2024/05/01/2023.09.14.23295564.abstract
AB Over three percent of people carry a dominant pathogenic variant, yet only a fraction of carriers develop disease. Disease phenotypes from carriers of variants in the same gene range from mild to severe. Here, we investigate underlying mechanisms for this heterogeneity: variable variant effect sizes, carrier polygenic backgrounds, and modulation of carrier effect by genetic background (marginal epistasis). We leveraged exomes and clinical phenotypes from the UK Biobank and the Mt. Sinai BioMe Biobank to identify carriers of pathogenic variants affecting cardiometabolic traits. We employed recently developed methods to study these cohorts, observing strong statistical support and clinical translational potential for all three mechanisms of variable carrier penetrance and disease severity. For example, scores from our recent model of variant pathogenicity were tightly correlated with phenotype amongst clinical variant carriers, they predicted effects of variants of unknown significance, and they distinguished gain-from loss-of-function variants. We also found that polygenic scores predicted phenotypes amongst pathogenic carriers and that epistatic effects can exceed main carrier effects by an order of magnitude.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the following funding sources awarded to V.A.A., N.Z, and E.E.K.: R01HG011345. This work was supported by the following funding sources awarded to A.W.: F31HG013462.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data Analysis was approved by IRB of UCLA waived ethnical approval for this work. This analysis was approved by UCLA under UK Biobank application 33127. This research has been conducted using UK Biobank data under application 33127 and is available through the UK Biobank Access Management System http://amsportal.ukbiobank.ac.uk/. Figure 1 generated with BioRender.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUK Biobank access was obtained via https://www.ukbiobank.ac.uk/enable-your-research. BioMe access was obtained via requests submitted to BioMe Biobank and Mount Sinai Data Warehouse. Databases also used in this work include: ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), gnomAD exomes v2.1 (https://gnomad.broadinstitute.org/), Cardiovascular Disease KP genetic association datasets (https://cvd.hugeamp.org/datasets.html), Global Lipids Genetics Consortium Results (https://csg.sph.umich.edu/willer/public/glgc-lipids2021/), PubMed (https://pubmed.ncbi.nlm.nih.gov/), and GoogleScholar (https://scholar.google.com/).